Clinical Trial

A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an investigator- and participant-blind, randomized, placebo-controlled, parallel-group, Phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of orally administered RO7795081 in otherwise healthy Chinese adult participants with obesity or overweight.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-08-11
critical Recruitment opened 2026-04-14
Trial Details
NCT Number NCT07499050
Lead Sponsor Hoffmann-La Roche
Conditions Healthy Volunteers, Overweight or Obesity
Enrollment 30 participants
Start Date 2026-03-30
Primary Completion 2027-01-09 (estimated)
Study Completion 2027-01-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-10